Tumor treatment is ushering in the era of ADC drugs. ADC is linked by a powerful cytotoxic payload drug and tumor-targeting antibody by a chemical linker, usually the drug-antibody ratio (DAR) is 3.5-4. The design principle is to directly deliver cytotoxic drugs to the tumor part through antibodies without harming healthy cells. ADC drugs approvedRead more